ADMA Biologics Faces Serious Scrutiny
ADMA Biologics, Inc. is currently under investigation due to potential violations of federal securities laws. This investigation by a prominent securities law firm, Bleichmar Fonti & Auld LLP, comes on the heels of a troubling announcement where the independent outside auditor, CohnReznick LLP, abruptly resigned.
The Impacts of the Auditor's Resignation
The resignation of CohnReznick LLP sent shockwaves through the market and was followed by a sharp decline in ADMA's stock price. On a single trading day, ADMA Biologics experienced a decline of over 20% in stock value. This significant depreciation has raised concerns among investors about the company's financial stability and transparency.
Understanding ADMA Biologics
As a biopharmaceutical company, ADMA Biologics specializes in the production and marketing of specialty biologics designed to treat immunodeficient patients and others at risk of specific infectious diseases. Through their innovative approach, they aim to deliver effective treatments to vulnerable patient populations.
What Should Investors Consider?
Investors who have shares in ADMA Biologics may have legal options available to them. Engaging with Bleichmar Fonti & Auld LLP will provide investors with insight into the next steps they can take. The firm operates on a contingency fee basis, meaning there are no upfront costs involved in seeking legal representation.
Taking Action and Legal Support
If you are a shareholder of ADMA Biologics, it might be wise to explore your legal options in light of this investigation. Submitting your information to the law firm could provide pathways for addressing any potential losses experienced due to the stock's decline.
How Can I Submit My Information?
Investors can easily submit their information through the firm's official website. This could be an essential step in seeking compensation for any suffered losses.
Who to Contact for Legal Support?
For personalized legal assistance, you can reach out to Ross Shikowitz directly via email at ross@bfalaw.com or through the firm's main line. They are keen to assist shareholders who might feel impacted by the recent developments.
Bleichmar Fonti & Auld LLP: Who Are They?
Bleichmar Fonti & Auld LLP is a recognized leader in representing plaintiffs in securities class action lawsuits and shareholder litigation. Their accolades underscore their commitment to achieving justice for their clients, including awards for their exceptional legal work in high-stake cases involving significant corporate damages.
Why Should This Matter to Investors?
The events surrounding ADMA Biologics highlight the importance of corporate governance and accountability. Investors are encouraged to remain vigilant regarding company disclosures and potential red flags, especially when dramatic changes in management occur.
Frequently Asked Questions
What led to the investigation of ADMA Biologics?
The investigation was prompted by the unexpected resignation of the company's independent auditor, raising concerns about compliance with securities laws.
How much did ADMA's stock decline?
ADMA's stock fell by over 20% in one trading session following the auditor's resignation announcement.
What are the potential legal options for ADMA shareholders?
Shareholders may contact Bleichmar Fonti & Auld LLP for potential legal representation and recovery options related to their investments.
Who should investors contact for more information?
Investors can reach out to Ross Shikowitz at Bleichmar Fonti & Auld LLP for inquiries regarding their legal options.
What does Bleichmar Fonti & Auld LLP specialize in?
The firm specializes in securities law, particularly in class actions and shareholder litigation, representing clients in complex financial disputes.
